Replies to post #154736 on Biotech Values

[mcbio]

You astutely questioned the potential market for a sub-q obesity drug. I'm getting drawn too far into this discussion about a company which I lack prior knowledge of or interest in

ARWR is working on follow-on versions of adipotide and essentially acknowledged that they will need a better version down the road. They talked about hopes of partnering the initial version in the clinic and follow-on versions that they are already working on. FWIW, shares more than doubled on the prior data for the drug in monkeys (#msg-68855813 ). If they can demonstrate weight loss in this initial trial in people, I would expect there to be potential for a very large jump at this valuation even if they ultimately need to improve the formulation. Obviously there are no guarantees the drug will show any weight-loss benefit in this initial trial. I'm tempted to gamble though given that they're not a one-trick pony and actually have a platform even if it is early stage.